New Therapeutic Targets May Benefit Leukemia Patients

New therapeutic targets and drugs may someday benefit people with certain types of leukemia or blood cancer. Pre-clinical and pharmacological models found that cancer cells with a mutation in the KIT receptor -- an oncogenic/cancerous form of the receptor -- in mast cell leukemia and acute myeloid leukemia can be stopped. read more

Read the whole article on

More from